How should a venlafaxine (Effexor) overdose be managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of Venlafaxine Overdose

For life-threatening venlafaxine overdose with cardiotoxicity (QRS prolongation, ventricular dysrhythmias, hypotension), administer intravenous sodium bicarbonate as it is reasonable to use for sodium channel blocker poisoning, and consider VA-ECMO for refractory cardiogenic shock. 1

Understanding Venlafaxine Toxicity

Venlafaxine acts as a sodium channel blocker in overdose, similar to tricyclic antidepressants, causing QRS prolongation, hypotension, seizures, ventricular dysrhythmias, and cardiovascular collapse 1. The 2023 American Heart Association guidelines specifically list venlafaxine among sodium channel blockers requiring this approach.

Clinical Presentation

The most commonly reported overdose symptoms include 2:

  • Tachycardia (most common)
  • Altered consciousness (somnolence to coma)
  • Seizures (occur in 5% of overdoses)
  • Mydriasis
  • Vomiting

Serious complications include:

  • ECG changes: QT prolongation, QRS prolongation, bundle branch block
  • Ventricular tachycardia and bradycardia
  • Hypotension and cardiovascular collapse
  • Serotonin syndrome
  • Rhabdomyolysis
  • Liver necrosis
  • Death

Immediate Management Algorithm

1. Airway, Breathing, Circulation

  • Ensure adequate airway, oxygenation, and ventilation 2
  • Intubate early if altered mental status or respiratory compromise
  • Continuous cardiac monitoring and vital signs

2. Decontamination (if presenting early)

  • Administer activated charcoal if patient presents within 1-2 hours of ingestion and can protect airway 2
  • Consider gastric lavage with large-bore orogastric tube (with airway protection) if performed soon after ingestion in symptomatic patients 2
  • Do NOT induce emesis 2

Important caveat: Research shows that combined single-dose activated charcoal plus whole bowel irrigation provides greater benefit than either alone (odds ratio 0.25 for seizures at mean dose of 2100 mg) 3. However, this is not standard practice and should be considered only in consultation with toxicology.

3. Cardiac Toxicity Management

Monitor ECG closely for:

  • QRS prolongation (>100 ms)
  • QTc prolongation
  • Terminal rightward axis deviation in lead aVR 1

If life-threatening cardiotoxicity develops:

  • Administer hypertonic sodium bicarbonate (1000 mEq/L in adults, 500 mEq/L in children) as IV bolus 1
  • This recommendation is based on the 2023 AHA guidelines stating it is "reasonable to use sodium bicarbonate to treat life-threatening cardiotoxicity caused by poisoning from sodium channel blockers other than tricyclic or tetracyclic antidepressants" (Class 2a, Level C-LD)

For refractory cardiogenic shock:

  • Consider VA-ECMO (veno-arterial extracorporeal membrane oxygenation) 1
  • This is reasonable per 2023 AHA guidelines (Class 2a, Level C-LD)
  • Case reports demonstrate successful use of ECMO for up to 11 days in massive venlafaxine overdose 4

4. Seizure Management

  • Administer benzodiazepines (diazepam or midazolam) for seizures 3
  • Seizures occur in approximately 5% of venlafaxine overdoses 3
  • Critical timing: 90% of seizures occur within 26 hours, with 25% occurring between 7-24 hours post-ingestion 3

5. Observation Period

Minimum observation times based on formulation 5:

  • Immediate-release venlafaxine: 18 hours (24 hours if co-ingestions)
  • Extended-release (XR) venlafaxine: 21 hours
  • The longest time to last seizure in a 10-year retrospective review was 24 hours 5

What Does NOT Work

  • Forced diuresis, dialysis, hemoperfusion, and exchange transfusion are NOT beneficial due to venlafaxine's large volume of distribution 2
  • No specific antidotes exist for venlafaxine 2

Emerging Therapies

Lipid emulsion therapy shows promise in animal models:

  • Swine studies demonstrate that vasopressin plus lipid emulsion resulted in higher survival rates and faster return of spontaneous circulation in venlafaxine-induced cardiac arrest 6
  • Consider in consultation with toxicology for refractory cardiovascular collapse, though this is not yet standard practice
  • One case report questions whether early lipid infusion might prevent progression to seizures, rhabdomyolysis, and liver failure 7

Risk Stratification

Dose-related seizure risk 3:

  • 1000 mg: 5% probability of seizure
  • 5000 mg: 19% probability of seizure
  • 10,000 mg: 75% probability of seizure

Mortality considerations: Venlafaxine overdose carries higher fatal outcome risk than SSRIs but lower than tricyclic antidepressants 2. However, venlafaxine-treated patients have higher baseline suicide risk factors, making it unclear how much is attributable to drug toxicity versus patient characteristics.

Key Pitfalls to Avoid

  1. Don't discharge patients early: Observe for minimum 18-24 hours as seizures can occur late
  2. Don't miss ECG changes: QRS prolongation and rightward axis deviation in aVR precede ventricular dysrhythmias
  3. Don't forget serotonin syndrome: Can occur, especially with co-ingestions
  4. Don't rely on dialysis: It won't work due to large volume of distribution
  5. Monitor for delayed cardiac toxicity: In massive overdoses, cardiac dysfunction can persist for 2 weeks until drug concentrations fall below 1000 mcg/L 4

Supportive Care

  • General supportive and symptomatic measures
  • Monitor for rhabdomyolysis, liver function abnormalities
  • Consider poison control center consultation for complex cases 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.